Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The last date to apply for this program is 18th January 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
This surpasses the number of approvals supported in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
The study will be published on the pre-print server, medRXiv, shortly
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The drug is priced at Rs 2000 for a course of 40 tablets
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
Subscribe To Our Newsletter & Stay Updated
